Search research articles
Contact Us
Filters
Showing results (21-30 of 161) with videos related to
Page
of 17
Sort By:
Cancer Chemotherapy and Pharmacology
|
August 25, 2016
Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies
Helen Swaisland, Ruth Plummer, Karen So, et al.
Hepatology (Baltimore, Md.)
|
December 25, 2019
Pembrolizumab as a Cause of Cholangiopathy in a Patient With Metastatic Melanoma
Laura Stuart, Beth Lambourne, Paul Turner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2008
Mechanisms of chemoresistance to alkylating agents in malignant glioma
Jann N Sarkaria, Gaspar J Kitange, C David James, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2002
Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies
Ruth Plummer, Michele Ghielmini, Paula Calvert, et al.
Pharmacoeconomics
|
October 12, 2013
Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal
Sophie Beale, Rumona Dickson, Adrian Bagust, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 26, 2008
Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery)
Janet S Graham, Ruth Plummer, Candice McCoy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2014
Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer
Alistair Ring, Duncan Wheatley, Helen Hatcher, et al.
Investigational New Drugs
|
July 13, 2010
Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas
Ramón Salazar, Ruth Plummer, Ana Oaknin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2009
Extraosseous pericardial Ewing's sarcoma
Fathi Azribi, Albiruni Ryan Abdul Razak, Georgina Bough, et al.
Trials
|
March 9, 2017
Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial
Amy Cranston, Deborah D Stocken, Elaine Stamp, et al.
Page
of 17
Search research articles
Search
Showing results (21-30 of 161) with videos related to
Sort By:
Page
of 17
Cancer Chemotherapy and Pharmacology
|
August 25, 2016
Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies
Helen Swaisland, Ruth Plummer, Karen So, et al.
Hepatology (Baltimore, Md.)
|
December 25, 2019
Pembrolizumab as a Cause of Cholangiopathy in a Patient With Metastatic Melanoma
Laura Stuart, Beth Lambourne, Paul Turner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2008
Mechanisms of chemoresistance to alkylating agents in malignant glioma
Jann N Sarkaria, Gaspar J Kitange, C David James, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2002
Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies
Ruth Plummer, Michele Ghielmini, Paula Calvert, et al.
Pharmacoeconomics
|
October 12, 2013
Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal
Sophie Beale, Rumona Dickson, Adrian Bagust, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 26, 2008
Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery)
Janet S Graham, Ruth Plummer, Candice McCoy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2014
Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer
Alistair Ring, Duncan Wheatley, Helen Hatcher, et al.
Investigational New Drugs
|
July 13, 2010
Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas
Ramón Salazar, Ruth Plummer, Ana Oaknin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2009
Extraosseous pericardial Ewing's sarcoma
Fathi Azribi, Albiruni Ryan Abdul Razak, Georgina Bough, et al.
Trials
|
March 9, 2017
Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial
Amy Cranston, Deborah D Stocken, Elaine Stamp, et al.
Page
of 17